Cancer Cell Biology

癌细胞生物学 癌症细胞生物学计划的目标是促进跨越现代细胞生物学关键主题的综合研究，特别是与癌症病因、预防和治疗相关的研究，通过建立或扩大适当的核心设施来增强成员的能力，并促进与其他北卡罗来纳大学LCCC基础、临床和人口科学计划的互动。项目研究是 围绕五个主要领域组织：血管生成与血管生物学、细胞黏附与细胞骨架、细胞周期、细胞信号、染色质调节与表观遗传学。计划的亮点包括发现：JmjC结构域(JMJD)家族的组蛋白去甲基酶和去甲基酶D0T1L在白血病发生中的作用的发现[Cell，2005]；Ted Salmon(当选为美国艺术与科学院院士，2006年)对着丝粒的控制和结构的发现(Cell，2005；Cell，2007；Cell，2009)；Jim Bear(被Howard Hughes医学研究所任命为早期职业科学家，2009年)在肌动蛋白结构分支控制中的新机制；Henrik Dohlman，新的RGS途径组件；由Bill Marzluff，组蛋白前mRNA处理的关键组件；和岳雄，胶质瘤的机制--代谢酶1DH1的突变和代谢酶的乙酰化。该项目由生物化学和生物物理学教授熊跃博士领导，他自1993年以来一直是该项目的成员，自2006年以来一直担任该项目的负责人。他以细胞周期控制、肿瘤抑制和泛素途径的研究而闻名。目前，该计划有47名成员，他们在2009年总共获得了3510万美元的外部资金(总成本)，其中包括610万美元的NCI资金。从2004年到2009年，出版物总数为1 245份；其中10%是方案内出版物，10%是方案间出版物。该方案的未来计划包括在新的领域有选择地招聘，并更加重视翻译研究以及方案内和方案间的互动。

Cancer Cell Biology The goal of the Cancer Cell Biology Program is to foster integrated research that spans key themes of modern cell biology, especially as they relate to cancer etiology, prevenfion and therapy, to enhance the capabilities of members through establishment or expansion of appropriate core facilities, and to promote interactions with other UNC LCCC basic, clinical and population science programs. Program research is organized around five major areas: angiogenesis & vascular biology, cell adhesion & cytoskeleton, cell cycle, cell signaling, and chromatin regulafion & epigenetics. Program highlights include the discoveries: by Yi Zhang (appointed as an Investigator of Howard Hughes Medical Institute, 2004) of the JmjC domain (JMJD) family of histone demethylases and the function of demethylase D0T1L in in leukemogenesis {Cell, 2005); by Ted Salmon (elected a member of the American Academy of Arts and Sciences, 2006) of the control and architecture of the kinetochore {Cell, 2005; Cell, 2007; Cell, 2009); by Jim Bear (appointed as Early Career Scientist by the Howard Hughes Medical Institute, 2009) of new mechanims in the control of actin architecture branching; by Henrik Dohlman of new RGS pathway components; by Bill Marzluff the key components of histone pre-mRNA processing; and by Yue Xiong of the mechanism underlying glioma-mutation of metabolic enzyme 1DH1 and acetylation of metabolic enzymes by acetylation. The Program is led by Dr. Yue Xiong, professor of Biochemistry & Biophysics, a Program member since 1993 and Leader since 2006. He is known for his studies of cell cycle control, tumor suppression and the ubiquitin pathway. At present, the Program has 47 members who have generated a total of $35.1 M (total cost) in extramural funding in 2009, including $6.1 million of NCI funding. From 2004 to 2009, the total number of publications was 1,245; 10% of which were intra-programmatic and 10% were inter-programmatic. Future plans for the Program include selective recruitment in new areas, and increased emphasis on translational studies and intra- and inter-programmatic interactions.